US 12,448,453 B2
Fully human anti-human CD22 chimeric antigen receptor and application thereof
Guang Hu, Nanjing (CN); Yongkun Yang, Nanjing (CN); Panpan Niu, Nanjing (CN); Guangrong Meng, Nanjing (CN); Wei Cheng, Nanjing (CN); and Jialu Mo, Nanjing (CN)
Assigned to Nanjing IASO Biotechnology Co., Ltd., Nanjing (CN)
Appl. No. 17/995,168
Filed by Nanjing IASO Biotechnology Co., Ltd., Nanjing (CN)
PCT Filed Apr. 2, 2021, PCT No. PCT/CN2021/085330
§ 371(c)(1), (2) Date Sep. 30, 2022,
PCT Pub. No. WO2021/197483, PCT Pub. Date Oct. 7, 2021.
Claims priority of application No. 202010254388.3 (CN), filed on Apr. 2, 2020.
Prior Publication US 2023/0174654 A1, Jun. 8, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 35/17 (2025.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); C07H 21/04 (2006.01); C07K 16/00 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/2851 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4212 (2025.01); A61P 35/00 (2018.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C07K 2317/21 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01)] 17 Claims
 
1. An anti-CD22 antibody molecule comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region comprises complementarity-determining regions selected from any of the following groups: wherein the light chain variable region comprises LCDR1 having the sequence set forth in SEQ ID NO: 13, LCDR2 having the sequence set forth in SEQ ID NO: 14, and LCDR3 having the sequence set forth in SEQ ID NO: 15, and the heavy chain variable region comprises HCDR1 having the sequence set forth in SEQ ID NO: 16, HCDR2 having the sequence set forth in SEQ ID NO: 17, and HCDR3 having the sequence set forth in SEQ ID NO: 18:
the light chain variable region comprises LCDR1 having the sequence set forth in SEQ ID NO: 1, LCDR2 having the sequence set forth in SEQ ID NO: 2, and LCDR3 having the sequence set forth in SEQ ID NO: 3, and the heavy chain variable region comprises HCDR1 having the sequence set forth in SEQ ID NO: 4, HCDR2 having the sequence set forth in SEQ ID NO: 5, and HCDR3 having the sequence set forth in SEQ ID NO: 6; or
the light chain variable region comprises LCDR1 having the sequence set forth in SEQ ID NO: 7, LCDR2 having the sequence set forth in SEQ ID NO: 8, and LCDR3 having the sequence set forth in SEQ ID NO: 9, and the heavy chain variable region comprises HCDR1 having the sequence set forth in SEQ ID NO: 10, HCDR2 having the sequence set forth in SEQ ID NO: 11, and HCDR3 having the sequence set forth in SEQ ID NO: 12.